U.S. Communications Stock News

If you are wondering whether Equifax stock offers value at its current price, or if it is still pricing in too much past optimism, this article breaks down what the numbers are actually saying. The stock last closed at US$172.24, with returns of 1.0% over the past week, a 5.6% decline over the past month, and year to date and 1 year returns of 19.5% and 33.8% declines respectively. These figures may affect how you think about both risk and potential reward. Recent headlines around Equifax...

Earnings reversal puts Stepan’s latest quarter in focus Stepan (SCL) is back on investors’ radar after first quarter 2026 results showed sales of US$604.51 million alongside a net loss of US$41.41 million, compared with net income a year earlier. See our latest analysis for Stepan. The shares have softened around the earnings release, with a 1-day share price return of a 1.55% decline and a 7-day share price return of a 3.55% decline. The 1-year total shareholder return of a 2.19% decline and...

Investors may be wondering if Royal Caribbean Cruises at around US$259 per share still offers value, or if most of the opportunity is already on the table. The stock has seen a mixed run, with a 0.2% move over the last week, a 5.2% decline over 30 days, an 8.4% decline year to date, a 15.1% return over the past year and a very large 3-year gain of about 3.4x. These moves come against a backdrop where investors have been watching the cruise sector closely and paying attention to factors such...

Wondering whether Plains GP Holdings is still reasonably priced after its strong run, or if expectations have gone too far? This breakdown will help you frame the stock's current value against its fundamentals. The stock last closed at US$24.23, with returns of 3.6% over 7 days, 0.7% over 30 days, 24.8% year to date and 52.0% over the past year, plus 128.0% over 3 years and 247.1% over 5 years. Recent coverage has focused on Plains GP Holdings as an established player in the midstream energy...

Bio-Techne stock: recent performance snapshot Bio-Techne (TECH) has drawn investor attention after a mixed stretch, with a small gain over the past month alongside a decline over the past 3 months and weaker multi year total returns. Against that backdrop, the stock last closed at US$54.74, with annual revenue of US$1.22b and net income of US$81.06m. This positions the company as a mid cap player in life science tools and diagnostics. See our latest analysis for Bio-Techne. Short term...

In late April 2026, Kontoor Brands’ board approved updated bylaws clarifying virtual shareholder meetings and tightening advance notice and proxy rules, while also declaring a regular quarterly cash dividend of US$0.53 per share payable on June 18, 2026, to shareholders of record on June 8, 2026. Alongside these governance and capital-return moves, a new Chaco x Wrangler collaboration extends the Wrangler brand into outdoor footwear and apparel, highlighting how Kontoor is pairing its...

Wondering if Teva Pharmaceutical Industries at around US$35.35 is still offering value or if most of the opportunity has already been reflected in the price? This article breaks down what the current valuation signals are really saying. The stock has posted returns of 13.1% over the past week, 17.5% over the last month, 14.2% year to date and 115.7% over the past year, with a very large 3 year gain and a 244.9% 5 year return that naturally raise questions about risk and reward at today’s...

Compass (NYSE:COMP) agreed to acquire a 51% controlling stake in a venture, expanding its influence over a key part of its residential real estate platform. The company also entered a three year alliance with Rocket to broaden its home listing inventory and give agents access to a wider set of buyer and seller opportunities. At the same time, Compass continues to face federal price fixing litigation that introduces ongoing legal and operational uncertainty for the business. Compass focuses...

H2O America stock: overview and recent performance H2O America (HTO) has drawn fresh attention after its recent name change from SJW Group in May 2025. This has prompted investors to reassess how the stock’s returns and fundamentals stack up today. The utility provider, focused on water and related services in the United States, recently closed at $57.32. Over the past month the stock shows a return of a 3.1% decline, while the past 3 months reflect an 8.8% gain and the year-to-date figure...

This article examines whether Intuit, trading at around US$406.99, is currently priced for opportunity or already reflects its strengths, and explains what the current valuation may be indicating. The stock has returned 4.4% over the last 7 days, while the 1-year return shows a 35.1% decline, which can influence how investors think about both upside potential and risk. Recent coverage has focused on how Intuit is positioning its core software platforms and product ecosystem, providing useful...

This article looks at whether Novavax, trading at around US$8.03, is attractively priced or potentially a value trap, by exploring what the current price may be implying about the stock. The stock has seen mixed returns, with a 0.5% decline over the last 7 days, a 4.3% gain over 30 days, 12.6% year to date, 28.1% over 1 year, 7.8% over 3 years and a 95.0% loss over 5 years. Recent headlines around Novavax have kept the stock in focus, particularly as investors reassess its prospects beyond...

The United States market remained flat over the last week, yet it has seen a significant rise of 28% over the past year, with earnings expected to grow by 16% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.

Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.

The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

The market remained flat over the last week, though it has risen 28% over the past year with earnings expected to grow by 16% annually. For investors willing to explore beyond well-known names, penny stocks—often representing smaller or newer companies—can still offer surprising value and potential for growth. In this article, we examine three penny stocks that combine financial strength with promising prospects in today's evolving market landscape.

Over the last 7 days, the United States market has remained flat, yet it is up 28% over the past year with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying stocks that are not only resilient but also poised for growth can uncover potential opportunities in lesser-known companies.

Over the last 7 days, the United States market has remained flat, yet it has experienced a substantial 28% rise over the past year. In this context of expected earnings growth of 16% per annum in the coming years, identifying dividend stocks that offer consistent payouts and potential for capital appreciation becomes crucial for investors seeking stability and income.

Why Knife River’s latest earnings matter for shareholders Knife River (KNF) reported first quarter revenue of US$410.1 million and a net loss of US$79.2 million, a combination that often prompts investors to reassess how the stock reflects the underlying business. See our latest analysis for Knife River. The earnings update and the recent disclosure that Vanguard Capital Management holds 5.25% of Knife River appear to sit alongside strong recent momentum, with a 30 day share price return of...

Ultra Clean Holdings recently reported first-quarter 2026 results, with revenue rising to US$533.7 million while posting a net loss of US$17.9 million, and concurrently announced the upcoming retirement of CFO Sheri Savage alongside a change in board chair later this month. The company also issued second-quarter guidance calling for higher revenue and a return to GAAP profitability and disclosed new insider trading plans and a Form 144 filing, adding fresh context to its capital structure...

Immunome has submitted a New Drug Application to the FDA for varegacestat, an oral once-daily gamma secretase inhibitor for adults with desmoid tumors, backed by a global Phase 3 RINGSIDE trial that met its primary and key secondary endpoints. A key insight is that RINGSIDE is the largest randomized study conducted in this rare tumor type, with data selected for oral presentation at the 2026 ASCO Annual Meeting, highlighting the clinical community’s interest in varegacestat’s profile. We’ll...

Recent performance snapshot LGI Homes (LGIH) has moved sharply in recent months, with the stock showing a one month gain of 17.7%, a past 3 months decline of 16.7%, and a 1 year total return decline of 19.8%. See our latest analysis for LGI Homes. At a share price of $44.88, LGI Homes has seen momentum fade recently, with a 1 day share price decline of 7.5% following a 30 day share price gain of 17.7%. The 1 year total shareholder return remains down 19.8%, which points to a stock still...

Trevi Therapeutics recently announced plans to present detailed Phase 2b CORAL trial results and additional nalbuphine ER data for IPF-related chronic cough at the ATS 2026 International Conference in Orlando on May 18, 2026. Alongside upcoming Q1 2026 results and a proposal to double authorized common shares, these scientific disclosures highlight how clinical and corporate actions may shape Trevi’s future options for funding and advancing Haduvio. We’ll now examine how the upcoming Phase...

Stock performance snapshot and recent context PTC Therapeutics (PTCT) has drawn investor attention after recent trading, with the stock last closing at $65.49. The company operates in the rare disease biopharma space, with products spanning Duchenne muscular dystrophy and spinal muscular atrophy. See our latest analysis for PTC Therapeutics. Recent trading has been choppy, with a 1-day share price return of 0.52% compared with a 90-day share price return of 12.48% and a 1-year total...

Leidos Holdings reported past first-quarter 2026 results with sales of US$4,400 million, higher than a year earlier, while net income and earnings per share from continuing operations decreased year on year. Alongside these earnings, Leidos secured multi‑hundred‑million‑dollar U.S. defense and health contracts and maintained its quarterly cash dividend, underscoring the scale of its government-backed backlog. Now we’ll examine how these sizeable new U.S. Army and Military OneSource awards...